{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T17:53:27Z","timestamp":1781805207872,"version":"3.54.5"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jacl.2026.02.010","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:31:53Z","timestamp":1771288313000},"page":"762-769","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Low-density lipoprotein cholesterol lowering and out-of-pocket cost of inclisiran therapy in the United States"],"prefix":"10.1016","volume":"20","author":[{"given":"Nihar R.","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9087-936X","authenticated-orcid":false,"given":"Nicholas W.","family":"Van Hise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan S.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.jacl.2026.02.010_bib1","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.038644","article-title":"Heart disease mortality in the United States, 1970\u20132022","volume":"14","author":"King","year":"2025","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"10.1016\/j.jacl.2026.02.010_bib2","first-page":"e596","article-title":"2019 ACC\/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jacl.2026.02.010_bib3","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1093\/ehjcvp\/pvac049","article-title":"Safety and efficacy of very low LDL-cholesterol intensive lowering: a meta-analysis and meta-regression of randomized trials","volume":"9","author":"Patti","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"12","key":"10.1016\/j.jacl.2026.02.010_bib4","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.jacl.2026.02.010_bib5","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2026.02.010_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2022.100336","article-title":"Lipid treatment status and goal attainment among patients with atherosclerotic cardiovascular disease in the United States: a 2019 update","volume":"10","author":"Gu","year":"2022","journal-title":"Am J Prev Cardiol"},{"issue":"9","key":"10.1016\/j.jacl.2026.02.010_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamacardio.2021.1810","article-title":"Use of lipid-lowering therapies over 2 years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US","volume":"6","author":"Cannon","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"25","key":"10.1016\/j.jacl.2026.02.010_bib8","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.jacl.2026.02.010_bib9","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1093\/eurjpc\/zwaf123","article-title":"Challenges in achieving LDL cholesterol targets and novel approaches to lipid lowering","volume":"32","author":"Malick","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2026.02.010_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/cells11192972","article-title":"PCSK9 inhibition: from current advances to evolving future","volume":"11","author":"Liu","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jacl.2026.02.010_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1339487","article-title":"PCSK9 inhibition: from effectiveness to cost-effectiveness","volume":"11","author":"Mercep","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacl.2026.02.010_bib12","first-page":"1078","article-title":"Impact of manufacturer-initiated list price reduction on patient out-of-pocket costs for\u00a0PCSK9\u00a0inhibitors","volume":"30","author":"Seo","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jacl.2026.02.010_bib13","unstructured":"LEQVIO (inclisiran) prescribing information. Novartis Pharmaceuticals Corporation. Accessed January 14, 2026.\u00a0https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/leqvio.pdf."},{"issue":"16","key":"10.1016\/j.jacl.2026.02.010_bib14","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.jacl.2026.02.010_bib15","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jacl.2026.02.010_bib16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"Ray","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.jacl.2026.02.010_bib17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamacardio.2016.4700","article-title":"National trends in statin use and expenditures in the US adult population from 2002 to 2013: insights from the Medical Expenditure Panel Survey","volume":"2","author":"Salami","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"12","key":"10.1016\/j.jacl.2026.02.010_bib18","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1001\/jamacardio.2017.3655","article-title":"Updated cost-effectiveness assessments of PCSK9 inhibitors from the perspectives of the health system and private payers: insights derived from the FOURIER Trial","volume":"2","author":"Arrieta","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"8","key":"10.1016\/j.jacl.2026.02.010_bib19","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s40261-022-01173-3","article-title":"Cost-effectiveness of icosapent ethyl, evolocumab, alirocumab, ezetimibe, or fenofibrate in combination with statins compared to statin monotherapy","volume":"42","author":"Michaeli","year":"2022","journal-title":"Clin Drug Investig"},{"issue":"1","key":"10.1016\/j.jacl.2026.02.010_bib20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/ehjqcco\/qcaa072","article-title":"Cost-effectiveness of proprotein convertase subtilisin\/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden","volume":"8","author":"Landmesser","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"5","key":"10.1016\/j.jacl.2026.02.010_bib21","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40256-022-00534-9","article-title":"Cost effectiveness of inclisiran in atherosclerotic cardiovascular patients with elevated low-density lipoprotein cholesterol despite statin use: a threshold analysis","volume":"22","author":"Desai","year":"2022","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jacl.2026.02.010_bib22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.atherosclerosis.2023.01.001","article-title":"Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: a single country, multicenter, observational study (AT-TARGET-IT)","volume":"366","author":"Gargiulo","year":"2023","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.jacl.2026.02.010_bib23","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/j.clinthera.2021.02.002","article-title":"Effectiveness, safety, and adherence to treatment of proprotein convertase subtilisin\/kexin type 9 inhibitors in real practice","volume":"43","author":"Gayoso-Rey","year":"2021","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.jacl.2026.02.010_bib24","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jacl.2020.11.004","article-title":"PCSK9 inhibition in clinical practice: treatment patterns and attainment of lipid goals in a large health maintenance organization","volume":"15","author":"Zafrir","year":"2021","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.jacl.2026.02.010_bib25","doi-asserted-by":"crossref","first-page":"e515","DOI":"10.1016\/j.jacl.2024.04.045","article-title":"Treatment patterns among early inclisiran vs anti\u2013PCSK9 mAbs users: a retrospective analysis of US Claims Databases","volume":"18","author":"Niu","year":"2024","journal-title":"J Clin Lipidol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426000437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426000437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:17:45Z","timestamp":1778833065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426000437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1933287426000437"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.02.010","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-density lipoprotein cholesterol lowering and out-of-pocket cost of inclisiran therapy in the United States","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}